The serendipitous discovery of exendin-4 led to the development of exenatide immediate-release (exenatide IR, Byetta), a synthetic version of exendin-4 with C-terminal amidation to enhance its stability [ Figure 2 , Table 1 ], which became the first FDA-approved GLP-1RA in 2005 for the treatment of T2DM in adults [ Table 2 ]
When side effects do occur, they are typically mild and dose-dependent
2 and 3
Increased Insulin Secretion: It facilitates enhanced insulin release, supporting lower blood sugar levels and promoting glucose storage as glycogen in the liver and muscles
Irregular infiltration into the surrounding bone, particularly in the maxillary bone as demonstrated in this case, can be seen
By optimising how your body uses fat for energy, it can help improve endurance and reduce the reliance on glycogen stores